Aug 2026· The Lancet Regional Health - Americas· Vol 62, pp. 101588· 0 citations· 48 references
Medicine
TL;DR
Key findings include increasing incidence, improved survival in recent cohorts, and a non-significant downward trend in mortality in Chile.
Abstract
Summary Background Cancer registries in Latin America continue to face challenges related to coverage, under-registration, and data quality. We evaluated childhood cancer epidemiology in Chile from 2007 to 2023, assessed the quality of the National Childhood Cancer Registry (RENCI) according to International Agency for Research on Cancer (IARC) standards, and described the childhood cancer control policy context. Methods We analysed 8821 incident cases in children aged 0–14 years registered in RENCI and classified according to ICD-O-3.2 and ICCC-3. Incidence and mortality rates were age-standardised using the Segi world standard population. Mortality and years of potential life lost (YPLL) were estimated using national mortality data (2002–2021). Trends were assessed using Joinpoint regression and five-year observed survival using the Kaplan–Meier method. Registry quality was evaluated according to IARC criteria. Findings Incidence increased from 137.4 to 143.0 per million (AAPC 1.36, 95% CI 0.5–2.4), with leukaemias remaining the most common cancer type (58.6 per million), followed by central nervous system tumours (24.8) and lymphomas (12.7). Five-year survival improved from 71.4% (95% CI 69.6–73.8) in 2007–2011 to 80.5% (95% CI 76.4–83.9) in 2020–2023. Mortality declined from 36.3 to 25.7 per million between 2002 and 2021 (AAPC –0.57, 95% CI –1.5 to 0.4). RENCI achieved 100% national coverage, an MV% of 93.5%, and a DCO% of 0.7%. Interpretation This study describes the implementation and operation of a national population-based childhood cancer registry in a middle-income country and reports its epidemiological findings. Key findings include increasing incidence, improved survival in recent cohorts, and a non-significant downward trend in mortality. These results offer practical insights for other low- and middle-income countries seeking to strengthen childhood cancer surveillance systems. The descriptive nature of the study and the temporal (non-causal) associations observed should be considered when interpreting the findings. Funding National Childhood Cancer Registry (RENCI) of the Ministry of Health of Chile.
The Argentina Oncopediatric Registry (ROHA), established in 2000, provides a unique framework for evaluating long-term trends in childhood cancer incidence, survival, and mortality and offers a model to improve equity, quality of care, and outcomes in Argentina.
Florencia Moreno, M. Chaplin, Mariana Nana et al.· Frontiers in Cancer Control...· 0 citations
Findings support timely diagnosis and appropriate care across age groups, continued screening among eligible individuals, and dynamic prognostic assessment in colorectal cancer.
M. Taborelli, F. Toffolutti, T. Angelin et al.· Digestive and Liver Disease· 0 citations
Abstract Background Early diagnosis of childhood cancer remains challenging because initial symptoms are common, nonspecific and have low predictive value in primary healthcare (PHC). We assessed whether socioeconomic differences shape pre-diagnostic PHC pathways before childhood cancer diagnosis. Methods We conducted...
Julia Reißinger, Christina-Evmorfia Kampitsi, M. Feychting et al.· BMJ Paediatrics Open· 0 citations
Objective: Central nervous system (CNS) tumours are the leading cause of cancer-related mortality among children and adolescents worldwide, surpassing leukaemia. Pakistan has a predominantly young population but lacks a national cancer mortality registry. This study aimed to characterize temporal trends and sex dispari...
M. Barakat, Hadi Flouni, Reena Bai et al.· JOURNAL OF PAKISTAN MEDICAL...· 0 citations
A consistent rise in pancreatic cancer-related mortality with an increasing trend for rural areas emphasizes the discrepancy and the possible need for targeted interventions.
Zuha Tariq, Alyaa Ahmed Ibrahim, Ahmed Khairy et al.· ASIDE Oncology· 0 citations